FDA approves VIG for smallpox shot complications

Smallpox

Feb 24, 2005 (CIDRAP News) – An intravenous form of vaccinia immune globulin (VIG), used to treat serious reactions to smallpox vaccine, has gained approval by the Food and Drug Administration (FDA) for the first time.

The FDA announced approval of Vaccinia Immune Globulin Intravenous (VIGIV) Feb 18. The product is made by DynPort Vaccine Co. LLC, based in Frederick, Md. DynPort is under a long-term contract to produce vaccines and related products for the Department of Defense (DoD).

VIG previously has been available only under "investigational new drug" (IND) rules. In older formulations, it could be injected only into muscle because it contained too much aggregated protein to be given intravenously, according to the Centers for Disease Control and Prevention (CDC).

VIG is derived from the plasma of people recently inoculated against smallpox; it contains antibodies to vaccinia, the virus used in the shot. VIGIV is made from plasma given by immunized US military personnel. The product is used to treat serious vaccinia complications such as generalized vaccinia, eczema vaccinatum, and progressive vaccinia.

The FDA said VIGIV was tested clinically in 111 volunteers and was well tolerated. "When adverse effects were noted, they were mild to moderate and included headaches, hives, and other rashes," the agency's news release said.

DynPort reported in August 2004 that it had tested VIGIV in separate studies involving 33 and 78 volunteers, none of whom had a serious reaction to the product. At the time, the company said VIGIV would be its first licensed product.

Current information on the CDC Web site says about 2,700 doses of VIG are available. In the past VIG was used at the rate of 47 doses per 1 million primary vaccinees and 2 doses per million revaccinees, according to the CDC. About 39,600 civilian healthcare personnel have received smallpox shots in the past 2 years in a CDC effort to prepare for the risk of a bioterrorist release of smallpox virus.

DynPort spokeswoman April Finnen referred questions about how many doses of VIGIV the company is making to DoD officials. As of this writing, DoD had not provided any information in response to questions asked yesterday.

In the current DoD smallpox vaccination program, three people have been treated with VIG out of 730,000 military personnel vaccinated as of Feb 21, according to the DoD's latest smallpox vaccination safety update. Two of the patients had ocular vaccinia infections and one was a burn patient.

Another company, Cangene, based in Winnipeg, Man., has a 5-year contract to produce up to 100,000 doses of VIG for the CDC. The product is in "late stage clinical development," according to the company Web site.

See also:

CDC information on VIG
http://www.bt.cdc.gov/agent/smallpox/vaccination/mgmt-adv-reactions.asp

DoD smallpox vaccination safety summary
http://www.smallpox.army.mil/event/SPSafetySum.asp

CDC VIG fact sheet for the public
http://www.bt.cdc.gov/agent/smallpox/vaccination/vig.asp

This week's top reads

  1. USDA suspends southern border livestock imports over New World screwworm threat

    As cattle detections track northward, Mexico recently reported its first human case.

    Lisa Schnirring
    screwworm larva

  2. Meta-analysis: Zika-infected pregnant moms 4 times more likely to have babies with microcephaly

    Five of 22 studies noted that over 50% of newborns had microcephaly, and the same number of studies observed that over 5% had congenital Zika syndrome. 

    Mary Van Beusekom

  3. Woman dies of Creutzfeldt-Jakob almost 50 years after taking prion-contaminated growth hormone

    The patient, who presented with gait imbalance and tremors, wasn't diagnosed until she was in a coma, shortly before she died.

    Mary Van Beusekom
    Woman in hospital bed

  4. HHS expected to discontinue COVID vaccine recommendations for some groups

    When CDC advisers widened their recommendation in 2023, most members were swayed by data, including those for long COVID, showing that no group is at low risk for the virus.

    Lisa Schnirring

  5. Data suggest COVID-19 reinfections less likely to cause long COVID

    The risk of long COVID was two to three times higher after the initial infection (14.8%) than after first (5.8%) or second (5.3%) reinfections.

    Stephanie Soucheray
    LONG COID

  6. FDA significantly limits COVID-19 vaccine recommendations

    Critics said today’s announcement is more evidence of the current administration’s willingness to undermine public trust in vaccines.

    Stephanie Soucheray
    FDA building

  7. Texas announces more measles cases, including first in Dallas area

    Two cases near the Dallas area are now included in the large outbreak, which now totals 717 cases.

    Lisa Schnirring

  8. WHO advisers say current strains OK for COVID vaccine production

    Current vaccine strains show high neutralization against the latest variants, but the LP.8.1 antigen may provide similar or moderately higher cross-reactive antibody response.

    Lisa Schnirring
    senior vaccination

  9. Saudi Arabia confirms 9 MERS cases, including hospital cluster

    Since 2023, the country has ramped up MERS-CoV testing as part of sentinel surveillance.

    Lisa Schnirring
    hospital isolation

  10. Flu vaccine efficacy 41% overall and 26% in older adults, per 2023-24 estimates

    Estimated effectiveness was 68% against influenza B and 32% against type A.

    Mary Van Beusekom
    Flu shot going into arm

Our underwriters